• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Balancing Benefits and Risks: Do Inhaled Corticosteroids Modify the Lung Microbiome?

作者信息

Singh Shivani, Pragman Alexa A, Segal Leopoldo N

机构信息

Division of Pulmonary and Critical Care Medicine New York University Grossman School of Medicine-NYU Langone Health New York, New York.

Department of Medicine Minneapolis Veterans Affairs Medical Center and University of Minnesota Minneapolis, Minnesota.

出版信息

Am J Respir Crit Care Med. 2021 Nov 15;204(10):1117-1119. doi: 10.1164/rccm.202109-2024ED.

DOI:10.1164/rccm.202109-2024ED
PMID:34554893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8759301/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b61/8759301/6a6e68c59ba2/rccm.202109-2024EDf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b61/8759301/6a6e68c59ba2/rccm.202109-2024EDf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b61/8759301/6a6e68c59ba2/rccm.202109-2024EDf1.jpg

相似文献

1
Balancing Benefits and Risks: Do Inhaled Corticosteroids Modify the Lung Microbiome?权衡利弊：吸入性糖皮质激素会改变肺部微生物群吗？
Am J Respir Crit Care Med. 2021 Nov 15;204(10):1117-1119. doi: 10.1164/rccm.202109-2024ED.
2
Inhaled corticosteroids: benefits and risks.吸入性糖皮质激素：益处与风险。
Thorax. 1992 Jun;47(6):404-7. doi: 10.1136/thx.47.6.404.
3
Weighing the benefits and risks of inhaled corticosteroids.权衡吸入性糖皮质激素的利弊。
Curr Opin Pulm Med. 2007 Mar;13(2):89. doi: 10.1097/MCP.0b013e328042bb0c.
4
Inhaled corticosteroids in COPD: quantifying risks and benefits.慢性阻塞性肺疾病中吸入性糖皮质激素：量化风险与益处
Thorax. 2013 Jun;68(6):499-500. doi: 10.1136/thoraxjnl-2012-202959. Epub 2012 Dec 15.
5
Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease.吸入性皮质类固醇与慢性阻塞性肺疾病中的肺炎。
Lancet Respir Med. 2014 Nov;2(11):919-932. doi: 10.1016/S2213-2600(14)70169-9. Epub 2014 Sep 17.
6
Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease.吸入性糖皮质激素在慢性阻塞性肺疾病中的益处与风险
Drug Saf. 2002;25(1):57-71. doi: 10.2165/00002018-200225010-00005.
7
Inhaled corticosteroids: benefits and risks.
J Asthma. 1996;33(1):5-16. doi: 10.3109/02770909609077758.
8
[Secondary osteoporosis: Inhaled corticosteroids induced osteoporosis in respiratory diseases].继发性骨质疏松症：呼吸系统疾病中吸入性糖皮质激素所致骨质疏松症
Clin Calcium. 2007 Jun;17(6):955-62.
9
[Local and systemic side effects of inhaled corticosteroids--what is reliable?].
Pneumologie. 1993 Mar;47(3):201-8.
10
The yin and the yang of immunosuppression with inhaled corticosteroids.
Thorax. 2013 Dec;68(12):1085-7. doi: 10.1136/thoraxjnl-2013-203773. Epub 2013 Aug 8.

引用本文的文献

1
Lung Microenvironment Among Patients with Nontuberculous Mycobacterial Pulmonary Disease by Metagenomic Sequencing Technique.采用宏基因组测序技术分析非结核分枝杆菌肺病患者的肺微环境
Biomedicines. 2025 Mar 28;13(4):818. doi: 10.3390/biomedicines13040818.
2
Rational use of inhaled corticosteroids for the treatment of COPD.COPD 的吸入性皮质类固醇的合理使用。
NPJ Prim Care Respir Med. 2023 Jul 24;33(1):27. doi: 10.1038/s41533-023-00347-6.
3
Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review.

本文引用的文献

1
Effects of Inhaled Corticosteroid/Long-Acting β-Agonist Combination on the Airway Microbiome of Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Clinical Trial (DISARM).吸入性皮质类固醇/长效β激动剂联合治疗对慢性阻塞性肺疾病患者气道微生物组的影响：一项随机对照临床试验（DISARM）。
Am J Respir Crit Care Med. 2021 Nov 15;204(10):1143-1152. doi: 10.1164/rccm.202102-0289OC.
2
Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease.吸入性皮质类固醇抑制抗菌肽导致慢性阻塞性肺疾病的微生态失调和细菌感染。
Sci Transl Med. 2019 Aug 28;11(507). doi: 10.1126/scitranslmed.aav3879.
3
吸入性皮质类固醇在非囊性纤维化支气管扩张症成人患者中的应用：从基础到临床。一篇叙述性综述。
Drugs. 2022 Sep;82(14):1453-1468. doi: 10.1007/s40265-022-01785-1. Epub 2022 Oct 20.
Chronic obstructive pulmonary disease upper airway microbiome is associated with select clinical characteristics.
慢性阻塞性肺疾病上呼吸道微生物群与某些临床特征有关。
PLoS One. 2019 Jul 23;14(7):e0219962. doi: 10.1371/journal.pone.0219962. eCollection 2019.
4
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.全球慢性阻塞性肺疾病诊断、管理和预防策略：GOLD 科学委员会报告 2019.
Eur Respir J. 2019 May 18;53(5). doi: 10.1183/13993003.00164-2019. Print 2019 May.
5
Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD.吸入皮质类固醇对 COPD 患者痰中细菌和病毒载量的长期影响。
Eur Respir J. 2017 Oct 5;50(4). doi: 10.1183/13993003.00451-2017. Print 2017 Oct.
6
Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung.阿奇霉素随机、双盲、安慰剂对照试验筛选出肺气肿肺中的抗炎性微生物代谢产物。
Thorax. 2017 Jan;72(1):13-22. doi: 10.1136/thoraxjnl-2016-208599. Epub 2016 Aug 2.
7
Lung microbiome dynamics in COPD exacerbations.COPD 加重期肺部微生物组动态变化。
Eur Respir J. 2016 Apr;47(4):1082-92. doi: 10.1183/13993003.01406-2015. Epub 2016 Feb 25.
8
Glucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function.糖皮质激素增强的胞葬作用通过降低肺泡巨噬细胞杀菌功能抑制小鼠肺部肺炎球菌清除。
J Immunol. 2015 Jul 1;195(1):174-84. doi: 10.4049/jimmunol.1402217. Epub 2015 May 18.
9
Chronic obstructive pulmonary disease lung microbiota diversity may be mediated by age or inhaled corticosteroid use.慢性阻塞性肺疾病的肺部微生物群多样性可能由年龄或吸入性糖皮质激素的使用介导。
J Clin Microbiol. 2015 Mar;53(3):1050. doi: 10.1128/JCM.03320-14.
10
Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease.慢性阻塞性肺疾病急性加重期的气道微生物群动态变化
J Clin Microbiol. 2014 Aug;52(8):2813-23. doi: 10.1128/JCM.00035-14. Epub 2014 May 21.